HGH vs Growth Hormone Secretagogues: Comparing the Research

One of the most common questions in growth-hormone research is the difference between supplying growth hormone directly versus using a secretagogue that prompts the body's own release. The distinction matters, and the research peptides involved work very differently.

Direct growth hormone: HGH (Somatropin, 191AA)

HGH (Somatropin, 191AA) is recombinant human growth hormone — the 191-amino-acid molecule itself. In research it supplies GH directly rather than stimulating endogenous production. See our HGH research overview.

Secretagogues: prompting natural release

Growth hormone secretagogues are peptides that signal the pituitary to release its own GH. They fall into two broad groups: GHRH analogs and ghrelin-mimetic GH-releasing peptides.

GHRH analogs: Sermorelin, CJC-1295, Tesamorelin

CJC-1295 and tesamorelin are GHRH analogs studied for their longer-acting stimulation of GH release. Sermorelin is the shorter-acting GHRH fragment. These mimic the body's own releasing hormone.

Ghrelin mimetics: Ipamorelin

Ipamorelin works on a separate, complementary pathway. Because GHRH analogs and ghrelin mimetics act through different receptors, they are often studied together — the basis of the popular CJC-1295 and ipamorelin combination.

Direct vs secretagogue: the key trade-off

The central distinction in the literature is that direct HGH supplies the hormone exogenously, while secretagogues stimulate pulsatile, endogenous release that follows the body's own feedback loops. Which approach a study uses depends on the research question.

Handling and storage

All of these compounds are supplied as lyophilized powder and reconstituted with bacteriostatic water. See our reconstitution guide for details.

Research use only. This article is educational and is not medical advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.